HRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.40%

Insider Buying (Last 12 Months): $260,650.00

Insider Selling (Last 12 Months): $0.00

Heron Therapeutics Insider Trading History Chart

Heron Therapeutics Share Price & Price History

^$3.05

▼ -0.05 (-1.61%)

As of 07/26/2024 01:00 AM ET

Days: 30 | 90 | 365

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

Heron Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/16/2023	Craig A Collard	CEO	Buy	150,000	$0.92	$138,000.00	186,496
11/16/2023	Ira Duarte	CFO	Buy	85,000	$0.89	$75,650.00	85,000
11/16/2023	William P Forbes	EVP	Buy	50,000	$0.94	$47,000.00	54,000
7/21/2023	Adam Morgan	Director	Buy	2,486,744	$1.37	$3,406,839.28	6,986,744
5/3/2022	Kimberly Manhard	EVP	Sell	1,504	$4.76	$7,159.04	10,872
12/21/2021	Christian Waage	Director	Sell	300	$9.73	$2,919.00
9/21/2021	Christian Waage	Director	Sell	300	$12.31	$3,693.00

I’m giving you the name of this investment for free

From Porter & Company | Ad

This key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.

Let me explain in this new documentary video

SEC Filings (Institutional Ownership Changes) for Heron Therapeutics (NASDAQ:HRTX)

80.01% of Heron Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Heron Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
7/26/2024	Legato Capital Management LLC	239,239	$0.84M	0.1%	N/A	0.159%
7/26/2024	Bank of New York Mellon Corp	449,212	$1.57M	0.0%	+33.9%	0.298%
7/24/2024	Zweig DiMenna Associates LLC	128,592	$0.45M	0.1%	-59.8%	0.085%
7/22/2024	Capital Investment Counsel Inc	14,625	$51K	0.0%	+27.2%	0.010%
7/17/2024	Baader Bank Aktiengesellschaft	36,128	$0.13M	0.0%	N/A	0.024%
7/16/2024	Apeiron RIA LLC	188,635	$0.66M	0.2%	+52.1%	0.125%
7/12/2024	Congress Park Capital LLC	1,578,501	$5.53M	2.2%	-4.0%	1.048%
7/12/2024	SG Americas Securities LLC	198,186	$0.69M	0.0%	N/A	0.132%
7/10/2024	Valeo Financial Advisors LLC	12,747	$45K	0.0%	N/A	0.008%
5/16/2024	California State Teachers Retirement System	10,409	$29K	0.0%	-38.9%	0.007%
5/15/2024	Price T Rowe Associates Inc. MD	29,922	$83K	0.0%	+15.4%	0.020%
5/14/2024	CM Management LLC	300,000	$0.83M	0.7%	-7.7%	0.199%
5/10/2024	Vanguard Group Inc.	8,114,716	$22.48M	0.0%	-2.7%	5.387%
5/9/2024	Monaco Asset Management SAM	1,813,164	$5.02M	1.5%	-18.6%	1.204%
5/9/2024	State Board of Administration of Florida Retirement System	40,705	$0.11M	0.0%	+51.4%	0.027%
5/8/2024	Headlands Technologies LLC	10,886	$30K	0.0%	N/A	0.007%
5/7/2024	Susquehanna Fundamental Investments LLC	11,727	$32K	0.0%	N/A	0.008%
5/3/2024	GSA Capital Partners LLP	279,699	$0.78M	0.1%	-17.6%	0.186%
5/1/2024	BNP Paribas Financial Markets	51,296	$0.14M	0.0%	+80.7%	0.034%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	32,615	$90K	0.0%	N/A	0.022%
4/30/2024	Commonwealth Equity Services LLC	338,526	$0.94M	0.0%	+3.1%	0.225%
4/18/2024	Diversified Trust Co	23,966	$66K	0.0%	N/A	0.016%
4/16/2024	Congress Park Capital LLC	1,644,785	$4.56M	2.0%	-8.6%	1.094%
4/5/2024	Los Angeles Capital Management LLC	493,264	$1.37M	0.0%	-4.1%	0.328%
2/15/2024	Orchard Capital Management LLC	2,243,426	$3.81M	1.2%	+4.7%	1.495%
2/9/2024	JW Asset Management LLC	2,292,418	$3.90M	2.2%	-4.8%	1.528%
2/9/2024	Franklin Resources Inc.	6,404,795	$10.89M	0.0%	-8.0%	4.268%
2/9/2024	D.A. Davidson & CO.	30,100	$51K	0.0%	-25.9%	0.020%
2/8/2024	Richmond Brothers Inc.	296,706	$0.50M	0.9%	+188.0%	0.198%
2/8/2024	Panagora Asset Management Inc.	139,113	$0.24M	0.0%	N/A	0.093%
2/7/2024	Monaco Asset Management SAM	2,226,475	$3.79M	1.1%	+219.5%	1.484%
2/6/2024	Los Angeles Capital Management LLC	514,377	$0.87M	0.0%	+49.9%	0.343%
2/5/2024	Victory Capital Management Inc.	19,929	$34K	0.0%	+30.2%	0.013%
2/5/2024	Pekin Hardy Strauss Inc.	36,470	$62K	0.0%	-38.3%	0.024%
1/31/2024	Knights of Columbus Asset Advisors LLC	83,482	$0.14M	0.0%	+100.0%	0.056%
1/30/2024	ACT Advisors LLC.	22,145	$38K	0.0%	N/A	0.015%
1/19/2024	Congress Park Capital LLC	1,798,650	$3.06M	1.5%	+205.3%	1.199%
1/16/2024	Raymond James Financial Services Advisors Inc.	48,309	$82K	0.0%	+61.2%	0.032%
11/15/2023	Tejara Capital Ltd	2,109,681	$2.17M	1.2%	+28.6%	1.499%
11/15/2023	Rubric Capital Management LP	26,713,503	$27.52M	1.0%	+127.3%	18.978%
11/15/2023	Adage Capital Partners GP L.L.C.	2,000,000	$2.06M	0.0%	+100.0%	1.421%
11/13/2023	Tejara Capital Ltd	2,109,681	$2.17M	1.6%	+28.6%	1.499%
11/9/2023	JW Asset Management LLC	2,407,418	$2.48M	1.1%	+9.1%	1.710%
11/8/2023	D.A. Davidson & CO.	40,600	$42K	0.0%	-84.2%	0.029%
11/8/2023	Pekin Hardy Strauss Inc.	59,095	$61K	0.0%	-44.3%	0.042%
11/7/2023	Monaco Asset Management SAM	696,908	$0.72M	0.2%	+72.1%	0.495%
11/7/2023	CM Management LLC	450,000	$0.46M	0.5%	-10.0%	0.320%
11/7/2023	New York State Common Retirement Fund	1,094,441	$1.13M	0.0%	-1.5%	0.778%
11/3/2023	Richmond Brothers Inc.	103,009	$0.11M	0.2%	+142.9%	0.073%
11/1/2023	Jacob Asset Management of New York LLC	327,450	$0.34M	0.5%	+18.2%	0.233%
10/27/2023	Allspring Global Investments Holdings LLC	41,034	$42K	0.0%	-30.4%	0.029%
10/24/2023	Bank of New York Mellon Corp	353,395	$0.36M	0.0%	+5.8%	0.251%
10/24/2023	Dakota Wealth Management	53,315	$55K	0.0%	N/A	0.038%
10/23/2023	Commonwealth Equity Services LLC	314,826	$0.32M	0.0%	+5.5%	0.224%
10/19/2023	Apeiron RIA LLC	83,000	$85K	0.0%	+59.6%	0.059%
10/13/2023	SG Americas Securities LLC	30,560	$31K	0.0%	N/A	0.022%
10/13/2023	Congress Park Capital LLC	589,150	$0.61M	0.3%	+15.2%	0.419%
9/21/2023	Barclays PLC	57,233	$65K	0.0%	-42.1%	0.041%
8/14/2023	X Square Capital LLC	31,185	$36K	0.0%	-78.9%	0.026%
8/14/2023	ArrowMark Colorado Holdings LLC	26,373	$31K	0.0%	-99.2%	0.022%
8/14/2023	Great Point Partners LLC	4,737,368	$5.50M	1.1%	-18.6%	3.957%
8/14/2023	Jefferies Financial Group Inc.	1,290,924	$1.50M	0.0%	N/A	1.078%
8/14/2023	Deep Track Capital LP	2,086,704	$2.42M	0.1%	-35.5%	1.482%
8/14/2023	Palisade Capital Management LP	4,143,649	$4.81M	0.1%	+4.4%	3.461%
8/14/2023	Graham Capital Management L.P.	169,148	$0.20M	0.0%	+576.4%	0.141%
8/11/2023	Searle & CO.	78,250	$0.13M	0.0%	+23.7%	0.065%
8/11/2023	Richmond Brothers Inc.	42,405	$49K	0.1%	N/A	0.035%
8/11/2023	JW Asset Management LLC	2,207,418	$2.56M	0.9%	N/A	1.844%
8/11/2023	Quinn Opportunity Partners LLC	72,097	$84K	0.0%	-21.7%	0.060%
8/11/2023	Franklin Resources Inc.	7,458,052	$8.65M	0.0%	-37.2%	6.230%
8/11/2023	Tejara Capital Ltd	1,640,133	$1.90M	0.9%	-1.6%	1.370%
8/11/2023	D.A. Davidson & CO.	256,407	$0.30M	0.0%	+15.8%	0.214%
8/10/2023	Jacob Asset Management of New York LLC	277,015	$0.32M	0.4%	-15.2%	0.231%
8/8/2023	Fisher Asset Management LLC	349,239	$0.41M	0.0%	-13.4%	0.292%
8/8/2023	Pekin Hardy Strauss Inc.	106,145	$0.12M	0.0%	-81.4%	0.089%
8/8/2023	Monaco Asset Management SAM	405,000	$0.47M	0.1%	N/A	0.338%
8/4/2023	CM Management LLC	500,000	$0.58M	0.6%	+42.9%	0.418%
8/3/2023	Los Angeles Capital Management LLC	339,474	$0.39M	0.0%	-51.9%	0.284%
7/25/2023	Raymond James Financial Services Advisors Inc.	32,950	$38K	0.0%	N/A	0.028%
7/24/2023	Allspring Global Investments Holdings LLC	58,935	$68K	0.0%	+85.8%	0.049%
7/20/2023	Apeiron RIA LLC	52,000	$60K	0.0%	+57.6%	0.043%
7/19/2023	Grimes & Company Inc.	47,804	$55K	0.0%	+26.8%	0.040%
7/18/2023	Allspring Global Investments Holdings LLC	58,935	$68K	0.0%	+85.8%	0.049%
7/14/2023	Congress Park Capital LLC	511,250	$0.59M	0.3%	+59.4%	0.427%
6/14/2023	State Board of Administration of Florida Retirement System	40,705	$61K	0.0%	-79.4%	0.034%
6/1/2023	Searle & CO.	63,250	$0.15M	0.0%	+90.2%	0.053%
5/16/2023	Great Point Partners LLC	5,817,368	$8.78M	1.7%	-8.5%	4.877%
5/15/2023	Quinn Opportunity Partners LLC	92,097	$0.14M	0.0%	N/A	0.077%
5/12/2023	Tejara Capital Ltd	1,667,519	$2.52M	1.3%	+237.8%	1.398%
5/11/2023	Jacob Asset Management of New York LLC	326,657	$0.49M	0.6%	+22.3%	0.274%
5/11/2023	M&T Bank Corp	89,280	$0.13M	0.0%	-39.8%	0.075%
5/10/2023	Simplify Asset Management Inc.	306,590	$0.46M	0.1%	N/A	0.257%
5/8/2023	Palisade Capital Management LP	3,970,286	$6M	0.2%	+4.9%	3.329%
5/8/2023	CM Management LLC	350,000	$0.53M	0.6%	+40.0%	0.293%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	32,615	$49K	0.0%	+49.4%	0.027%
5/4/2023	Los Angeles Capital Management LLC	705,677	$1.07M	0.0%	+320.9%	0.592%
4/28/2023	SG Americas Securities LLC	100,968	$0.15M	0.0%	N/A	0.085%
4/28/2023	Zweig DiMenna Associates LLC	121,630	$0.18M	0.0%	-13.6%	0.102%
4/27/2023	Arizona State Retirement System	34,448	$52K	0.0%	+18.9%	0.029%
4/25/2023	D.A. Davidson & CO.	221,445	$0.33M	0.0%	+27.4%	0.186%

Data available starting January 2016

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Today's Range

Now: $3.05

$3.03

$3.16

50 Day Range

MA: $3.34

$2.74

$3.86

52 Week Range

Now: $3.05

$0.50

$3.93

Volume

1,695,541 shs

Average Volume

2,602,803 shs

Market Capitalization

$459.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8

Who are the company insiders with the largest holdings of Heron Therapeutics?: Heron Therapeutics' top insider shareholders include:
Adam Morgan (Director)
Craig A Collard (CEO)
Ira Duarte (CFO)
William P Forbes (EVP)
Learn More about top insider investors at Heron Therapeutics.
Who are the major institutional investors of Heron Therapeutics?: Heron Therapeutics' top institutional shareholders include:
Congress Park Capital LLC — 1.05%
Bank of New York Mellon Corp — 0.30%
Legato Capital Management LLC — 0.16%
SG Americas Securities LLC — 0.13%
Apeiron RIA LLC — 0.13%
Zweig DiMenna Associates LLC — 0.09%
Learn More about top institutional investors of Heron Therapeutics stock.
Which institutional investors are selling Heron Therapeutics stock?: Within the last quarter, HRTX stock was sold by these institutional investors:
Zweig DiMenna Associates LLC
Congress Park Capital LLC
Which institutional investors are buying Heron Therapeutics stock?: In the previous quarter, HRTX stock was bought by institutional investors including:
Legato Capital Management LLC
SG Americas Securities LLC
Bank of New York Mellon Corp
Apeiron RIA LLC
Baader Bank Aktiengesellschaft
Valeo Financial Advisors LLC
Capital Investment Counsel Inc
Within the last year, these company insiders have bought Heron Therapeutics stock:
Adam Morgan (Director)
Craig A Collard (CEO)
Ira Duarte (CFO)
William P Forbes (EVP)
Learn More investors buying Heron Therapeutics stock.